分享产品介绍 评论(0)
物种
Human分子别名
SGRF, IL-23p19, CLMF p40, IL-12 subunit p40, NKSF2Accession
Q9NPF7, P29460表达序列
p19: Arg20-Pro189, with N-terminal His Tag
p40: Ile23-Ser328表达宿主
CHO分子量
p19: 18-22 kDa (Reducing) p40: 38-42 kDa (Reducing)
纯度
>95% by SDS-PAGE and HPLC.内毒素含量
<0.1EU/μg活性
EC50 = 1.26-2.13 ng/ml标记
Unconjugated标签
His Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Nature. 2010 Apr 29;464(7293):1371-5.
Nat Med. 2015 Jul;21(7):719-29.
Interleukin-23 (IL-23) is a heterodimeric pro-inflammatory cytokine belonging to the IL-12 family, primarily secreted by dendritic cells and macrophages. Composed of a unique p19 subunit and a shared p40 subunit with IL-12, IL-23 functions through a receptor complex consisting of IL-12Rβ1 and the IL-23-specific receptor subunit IL-23R.
IL-23 is recognized as a key upstream regulator in multiple autoimmune diseases, including psoriasis, inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and multiple sclerosis (MS). Genome-wide association studies have identified IL-23R gene variants linked to susceptibility for psoriasis, IBD, and Behçet's disease. In the gut, IL-23 exhibits a selective inflammatory profile, controlling local IL-17 production while sparing systemic immunity, making it an attractive therapeutic target that preserves host defense mechanisms.
电泳
2μg (R: reducing condition, N: non-reducing condition).
反相高效液相色谱(RP-HPLC)
>95% as determined by RP-HPLC.
ELISA
Immobilized IL-23 Protein, Human (Cat. No. UA040502) at 2.0μg/mL (100μL/well) can bind IL-12 R beta 1 Fc Chimera Protein, Human (Cat. No. UA010956) with EC50 of 1.26-2.13 ng/mL.
评论(0)